Redeye publishes a follow-up note subsequent to yesterday's conference call concerning sunday's CRL from the FDA. We make revisions to our assumptions for Ximluci in the US market, resulting in a lower base case. We also discuss the financing outlook.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se